M&A inflation just pushed the average biopharma valuation to a scary new peak
The consultants at Novasecta have been crunching the numbers on biopharma M&A for the past few years and concluded that a lot more of these …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
